Heterogeneity in endocrine monitoring and timing of endocrinology involvement during immune checkpoint inhibitor therapy: A Real-World Single-Center study.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
103 patients (67 men, 36 women; mean age 60.
I · Intervention 중재 / 시술
no endocrine follow-up during ICI therapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
OpenAlex 토픽 ·
Cancer Immunotherapy and Biomarkers
Multiple and Secondary Primary Cancers
Lung Cancer Research Studies
[PURPOSE] Endocrine immune-related adverse events (irAEs) are increasingly encountered with immune checkpoint inhibitors (ICIs), yet patterns of screening, referral, and emergency outcomes remain unde
- 95% CI 1.33–8.08
- RR 3.29
APA
Selin Tekin, Seda Hanife Oğuz, et al. (2026). Heterogeneity in endocrine monitoring and timing of endocrinology involvement during immune checkpoint inhibitor therapy: A Real-World Single-Center study.. Endocrine, 91(1). https://doi.org/10.1007/s12020-026-04589-5
MLA
Selin Tekin, et al.. "Heterogeneity in endocrine monitoring and timing of endocrinology involvement during immune checkpoint inhibitor therapy: A Real-World Single-Center study.." Endocrine, vol. 91, no. 1, 2026.
PMID
41920431 ↗
Abstract 한글 요약
[PURPOSE] Endocrine immune-related adverse events (irAEs) are increasingly encountered with immune checkpoint inhibitors (ICIs), yet patterns of screening, referral, and emergency outcomes remain underexplored. This study evaluated the adequacy of endocrine monitoring, iming of endocrinology involvement, and determinants of endocrine emergencies in ICI-treated patients.
[METHODS] We retrospectively reviewed 103 patients (67 men, 36 women; mean age 60.8 ± 12.1 years) referred to the Endocrinology Department between 2016 and 2025. Clinical data, cancer types, immunotherapy regimens, hormonal assessments, and causes and timing of referral were analyzed.
[RESULTS] Most patients (93.3%) were referred due to newly developed endocrine irAEs, with endocrinology involvement occurring at a median of 7.4 months (≈ 10th therapy cycle) after ICI initiation. The predominant ICI regimen involved PD-1 inhibitors (66%). Thyroid dysfunction ( = 64), secondary adrenal insufficiency ( = 28), and hyperglycemia ( = 4) were the leading endocrinopathies; hypophysitis was detected in 7 cases. Before ICI treatment, endocrine evaluation was absent in 22.3% and incomplete in 38.2%, while 9.7% received no endocrine follow-up during ICI therapy. Emergency admissions occurred in 17.4%, mainly due to adrenal crisis ( = 12), followed by thyrotoxicosis ( = 3). Although baseline screening status and timing of endocrinology involvement were not associated with emergency risk, phenotype strongly influenced outcomes: central adrenal insufficiency increased risk (RR = 3.29; 95% CI 1.33–8.08; = 0.0197).
[CONCLUSIONS] Endocrine irAEs are frequent and may be recognized only after clinical deterioration, exposing patients to preventable endocrine emergencies, particularly adrenal crisis. These findings highlight heterogeneity and gaps in endocrine surveillance during ICI therapy and support early, structured oncologist–endocrinologist collaboration with standardized baseline and follow-up assessments to improve patient safety and continuity of immunotherapy.
[METHODS] We retrospectively reviewed 103 patients (67 men, 36 women; mean age 60.8 ± 12.1 years) referred to the Endocrinology Department between 2016 and 2025. Clinical data, cancer types, immunotherapy regimens, hormonal assessments, and causes and timing of referral were analyzed.
[RESULTS] Most patients (93.3%) were referred due to newly developed endocrine irAEs, with endocrinology involvement occurring at a median of 7.4 months (≈ 10th therapy cycle) after ICI initiation. The predominant ICI regimen involved PD-1 inhibitors (66%). Thyroid dysfunction ( = 64), secondary adrenal insufficiency ( = 28), and hyperglycemia ( = 4) were the leading endocrinopathies; hypophysitis was detected in 7 cases. Before ICI treatment, endocrine evaluation was absent in 22.3% and incomplete in 38.2%, while 9.7% received no endocrine follow-up during ICI therapy. Emergency admissions occurred in 17.4%, mainly due to adrenal crisis ( = 12), followed by thyrotoxicosis ( = 3). Although baseline screening status and timing of endocrinology involvement were not associated with emergency risk, phenotype strongly influenced outcomes: central adrenal insufficiency increased risk (RR = 3.29; 95% CI 1.33–8.08; = 0.0197).
[CONCLUSIONS] Endocrine irAEs are frequent and may be recognized only after clinical deterioration, exposing patients to preventable endocrine emergencies, particularly adrenal crisis. These findings highlight heterogeneity and gaps in endocrine surveillance during ICI therapy and support early, structured oncologist–endocrinologist collaboration with standardized baseline and follow-up assessments to improve patient safety and continuity of immunotherapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The ULK1-NCOA3 axis restrains de novo lipogenesis and prevents diet-induced steatohepatitis and fibrosis in mice.
- Subgroup-specific predictive biomarkers in peripheral blood lymphocyte subsets for immune checkpoint inhibitor response in advanced esophageal squamous cell carcinoma: a prospective study.
- Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experience.
- Crosstalk between tumor-associated macrophages and the B7/CD28 family in immune checkpoint inhibitor-induced immunotherapy.
- Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions.
- Temporal association of diffuse large B-cell lymphoma with PD-1 inhibitor therapy in a patient with gastric adenocarcinoma: a case report.